{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-047951","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.806827+00:00","generated_at":"2026-06-10T18:56:58.395345+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Eledon Pharmaceuticals appoints James Robinson to board effective Oct 1, 2023","bullets":["Robinson will serve as chair of the Compensation Committee and member of Audit Committee.","Annual cash retainers of $42k for board service, $15.75k as comp chair, $10.5k for audit committee.","Granted option to purchase 150,437 shares vesting over two years at market price on grant date.","Board determined Robinson qualifies as independent under Nasdaq rules; no family relationships or arrangements."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-047951","json":"https://secwatch.observer/filing/0000950170-23-047951.json","markdown":"https://secwatch.observer/filing/0000950170-23-047951.md","text":"https://secwatch.observer/filing/0000950170-23-047951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023047951/0000950170-23-047951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023047951/eldn-20230911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T18:56:58.395345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0e966f099","claim":"James Robinson was appointed as director at Eledon Pharmaceuticals, Inc..","evidence_excerpt":"On September 11, 2023, James Robinson was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023047951/0000950170-23-047951-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}